From 2019-22, we were rank outsiders in an industry grappling with a once a century pandemic. Elon Musk famously said "Starting a company is like eating glass and staring into the abyss." In those years we stared deep into the abyss while eating glass everyday!
2023, was a turning point, and we will forever be grateful to the team at Mayo Clinic Platform_Accelerate, Popular Impact Fund (our first institutional investors), Lucem Health (our first customer), and ofcourse the FDA (for our first regulatory clearance).
2024, though one of the hardest years of my personal life, has been a year where AccurKardia built momentum throughout:
Jan: Moin Hussaini (ex Canon Medical, Vyaire, Edwards, Toshiba Medical, GE Healthcare) joined us as our CPO.
Mar: Med Tech stalwart, Ken Nelson (ex Biotelemtry/Phillips, Bardy/Baxter, and iRhythm), and payer guru, Francisco "KIKI" Martorell (ex Blue Cross Blue Shield and Venture Partners) joined us as Senior Advisors.
Jun: 1 of 65 companies (pool > 1300) accepted into MedTech Innovator's (MTI) 12th cohort. MTI is the worlds leading accelerator for Seed-Series C companies in Life Sciences.
Jun: 1 of 5 companies (pool > 400) accepted into MTI's inaugural Heart and Brain track sponsored by the American Heart Association.
Jun: Runner-ups at the Shark Tank event at the India Global Forum. Sharing space with luminaries like Abhinav Bindra (India's first individual Olympic Gold Medalist), Nawazuddin Siddiqui (one of the best actors of our generation), and Dr. Deepa Malik (India's first Paralympic medalist) was an incredible honor for a deep-tech company with Indian roots.
Sep: Announced as 1 of 5 finalist for MTI's Execution Award. and invited to present at AdvaMed. The award recognizes strong leadership teams and successful execution in improving patient care.
Sep: Groundbreaking abstract published in the Heart Rhythm Society journal by researchers from The Texas Heart Institute on AK-AVS, our first novel use case for ECGs. AK-AVS detects Aortic Stenosis (AS) using an ECG (traditionally requiring an echo). Beyond detecting AS, the study showed significant predictive value in identifying patients at risk of developing AS or Heart Failure within 5-years.
Oct: Obtained FDA breakthrough designation (our first) for AK-AVS.
Oct: Rising Star Finalist in the Provider Diagnostics category for AK-AVS in The Digital Health Hub Foundation - Digital Health Awards - the Oscars for Digital Health.
Oct: Invited to present at TCT2024 during a special session on AI-Driven Innovations in Heart Diagnostics and Imaging.
Dec: We have had some huge wins - but are keeping them under wraps for now 😊 (stay tuned!)
Don’t get me wrong, we still eat glass everyday, but stare into the abyss a lot less 😂
A big thank you to everyone that’s been with us from the start and to those that have joined us along the way towards establishing ECG as a broad biomarker, transforming healthcare, and saving lives!
Wishing everyone a brilliant 2025!
2024 has been an amazing year for AccurKardia—and we’re just getting started! Check out our video for a peek at this year’s highlights, and stay tuned for what’s on the horizon in 2025.
Wishing you all a happy, healthy, and prosperous New Year!
#2024Highlights #NewYear #Innovation #ECG #BetterOutcomes
Congratulations to the team !